Compare CAE & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | ROIV |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 28.7B |
| IPO Year | 2002 | 2021 |
| Metric | CAE | ROIV |
|---|---|---|
| Price | $24.08 | $35.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $29.93 | ★ $48.08 |
| AVG Volume (30 Days) | 780.5K | ★ 6.9M |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $1.98 | $530.75 |
| Revenue Next Year | $1.84 | $685.92 |
| P/E Ratio | $35.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.76 | $15.25 |
| 52 Week High | $34.24 | $42.50 |
| Indicator | CAE | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 46.25 |
| Support Level | $23.99 | $33.15 |
| Resistance Level | $27.11 | $37.59 |
| Average True Range (ATR) | 0.57 | 1.21 |
| MACD | 0.05 | -0.40 |
| Stochastic Oscillator | 34.56 | 22.31 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: i) Civil Aviation: Provides comprehensive training solutions for flight, cabin, maintenance, ground personnel and air traffic controllers in commercial, business and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training and crew sourcing services, as well as airline operations digital solutions; and ii) Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.